Form 8-K - Current report:
SEC Accession No. 0001213900-25-003401
Filing Date
2025-01-14
Accepted
2025-01-14 16:00:25
Documents
13
Period of Report
2025-01-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0227340-8k_raphael.htm   iXBRL 8-K 25606
  Complete submission text file 0001213900-25-003401.txt   192209

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE raph-20250108.xsd EX-101.SCH 3054
3 XBRL LABEL FILE raph-20250108_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE raph-20250108_pre.xml EX-101.PRE 22385
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0227340-8k_raphael_htm.xml XML 3221
Mailing Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108
Business Address SUITE 105 - 5348 VEGAS DR. LAS VEGAS NV 89108 702-442-1166
Raphael Pharmaceutical Inc. (Filer) CIK: 0001415397 (see all company filings)

EIN.: 260204284 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-53002 | Film No.: 25529356
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)